Cargando…

How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study

Medication non-adherence is common among patients with systemic lupus erythematosus (SLE) and may lead to poor clinical outcomes. Our aim was to identify influenceable contributors to medication non-adherence and suggest interventions that could increase adherence. Patients with SLE from two Swedish...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emamikia, Sharzad, Gentline, Cidem, Enman, Yvonne, Parodis, Ioannis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999748/ https://www.ncbi.nlm.nih.gov/pubmed/35407466 http://dx.doi.org/10.3390/jcm11071857

Ejemplares similares

Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2020)

Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus
por: Borg, Alexander, et al.
Publicado: (2023)

Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2021)

Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2020)

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
por: Emamikia, Sharzad, et al.
Publicado: (2022)

EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2022)

EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2021)

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2019)

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
por: Gomez, Alvaro, et al.
Publicado: (2023)

Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State
por: Hua, Nicole, et al.
Publicado: (2023)

Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE
por: Borg, Alexander, et al.
Publicado: (2021)

Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver’s Seat in Their Disease Monitoring?
por: Parodis, Ioannis, et al.
Publicado: (2022)

Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
por: Sjöwall, Christopher, et al.
Publicado: (2022)

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
por: Nikolopoulos, Dionysis, et al.
Publicado: (2023)

B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
por: Parodis, Ioannis, et al.
Publicado: (2020)

B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools
por: Parodis, Ioannis, et al.
Publicado: (2022)

Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management
por: Dey, Mrinalini, et al.
Publicado: (2021)

Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade
por: Lindblom, Julius, et al.
Publicado: (2022)

How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?
por: Kamen, Diane L
Publicado: (2009)

Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
por: Richter, Patricia, et al.
Publicado: (2023)

COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
por: Giannopoulou, Nefeli, et al.
Publicado: (2023)

Concerns of patients with systemic lupus erythematosus and adherence to therapy – a qualitative study
por: Farinha, Filipa, et al.
Publicado: (2017)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?
por: Pike, Marilyn C., et al.
Publicado: (2012)

B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2022)

Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
por: Parodis, Ioannis, et al.
Publicado: (2023)

Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
por: Lekpa, Fernando Kemta, et al.
Publicado: (2021)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

Association of patient copayment and medication adherence in systemic lupus erythematosus
por: Lomanto Silva, Raisa, et al.
Publicado: (2023)

Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?
por: Fazzari, Melissa J, et al.
Publicado: (2022)

Prediction of prognosis and renal outcome in lupus nephritis
por: Parodis, Ioannis, et al.
Publicado: (2020)

How can we accurately measure disease activity during pregnancy in systemic lupus erythematosus? New insights from the BILAG-2004 Pregnancy Index
por: Ali, Sasha, et al.
Publicado: (2023)

ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized
por: Farhangian, Michael E., et al.
Publicado: (2015)

Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision‐Making in Systemic Lupus Erythematosus Treatment?
por: Almeida‐Brasil, Celline C., et al.
Publicado: (2022)

Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?
por: Parodis, Ioannis, et al.
Publicado: (2022)

Correction to: How can we accurately measure disease activity during pregnancy in systemic lupus erythematosus? New insights from the BILAG-2004 Pregnancy Index
Publicado: (2023)

The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?
por: Piga, Matteo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nnerbggl5ciaphuli9lbbm861c